C. Rinaldi

发表

Optimizing the identification of risk‐relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families

I. Screpanti, G. Giannini, L. Ottini, 2017, Cancer medicine.

retSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid-inducible and frequently deleted in human neuroblastoma cell lines.

I. Screpanti, C. Thiele, G. Giannini, 2002, Cancer research.

The tumor suppressor gene KCTD11REN is regulated by Sp1 and methylation and its expression is reduced in tumors

M. Mancarelli, A. Gulino, E. Ferretti, 2010, Molecular Cancer.

Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?

I. Screpanti, G. Giannini, E. Ricevuto, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular mechanism of HMGA1 deregulation in human neuroblastoma.

G. Giannini, A. Gulino, F. Cerignoli, 2005, Cancer letters.

High mobility group A1 is a molecular target for MYCN in human neuroblastoma.

I. Screpanti, C. Dominici, G. Giannini, 2005, Cancer research.

Human papilloma virus-dependent HMGA1 expression is a relevant step in cervical carcinogenesis.

I. Screpanti, G. Giannini, L. Frati, 2008, Neoplasia.

Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families

I. Screpanti, G. Giannini, E. Ricevuto, 2006, Breast Cancer Research and Treatment.

Clinical classification of BRCA1 DNA missense variants: H1686Q is a novel pathogenic mutation occurring in the ontogenetically invariant THV motif of the N-terminal BRCT domain.

I. Screpanti, G. Giannini, E. Ricevuto, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human MRE11 is inactivated in mismatch repair‐deficient cancers

Alessandra Viel, Fabio Cerignoli, Marco Crescenzi, 2002, EMBO reports.

Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software

I. Screpanti, G. Giannini, E. Ricevuto, 2006, European Journal of Human Genetics.

MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response

I. Screpanti, C. Dominici, H. McDowell, 2010, Molecular Cancer Research.

Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability

I. Screpanti, A. Viel, G. Giannini, 2004, Oncogene.

Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families

I. Screpanti, G. Giannini, E. Ricevuto, 2007, Breast Cancer Research and Treatment.

BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.

A Gulino, I. Screpanti, G. Giannini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.